Cargando…
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB’s mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations, MYCN amplification is the most correlated event with poor out...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049239/ https://www.ncbi.nlm.nih.gov/pubmed/36982482 http://dx.doi.org/10.3390/ijms24065408 |
_version_ | 1785014407830437888 |
---|---|
author | De Rosa, Piergiuseppe Severi, Federica Zadran, Suleman Khan Russo, Marco Aloisi, Sara Rigamonti, Alberto Capranico, Giovanni Milazzo, Giorgio Perini, Giovanni |
author_facet | De Rosa, Piergiuseppe Severi, Federica Zadran, Suleman Khan Russo, Marco Aloisi, Sara Rigamonti, Alberto Capranico, Giovanni Milazzo, Giorgio Perini, Giovanni |
author_sort | De Rosa, Piergiuseppe |
collection | PubMed |
description | Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB’s mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations, MYCN amplification is the most correlated event with poor outcomes. MYCN is involved in the regulation of several cellular mechanisms, including cell cycle. Thus, studying the influence of MYCN overexpression in the G1/S transition checkpoint of the cell cycle may unveil novel druggable targets for the development of personalized therapeutical approaches. Here, we show that high expression of E2F3 and MYCN correlate with poor prognosis in NB despite the RB1 mRNA levels. Moreover, we demonstrate through luciferase reporter assays that MYCN bypasses RB function by incrementing E2F3-responsive promoter activity. We showed that MYCN overexpression leads to RB inactivation by inducing RB hyperphosphorylation during the G1 phase through cell cycle synchronization experiments. Moreover, we generated two MYCN-amplified NB cell lines conditionally knockdown (cKD) for the RB1 gene through a CRISPRi approach. Indeed, RB KD did not affect cell proliferation, whereas cell proliferation was strongly influenced when a non-phosphorylatable RB mutant was expressed. This finding revealed the dispensable role of RB in regulating MYCN-amplified NB’s cell cycle. The described genetic interaction between MYCN and RB1 provides the rationale for using cyclin/CDK complexes inhibitors in NBs carrying MYCN amplification and relatively high levels of RB1 expression. |
format | Online Article Text |
id | pubmed-10049239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100492392023-03-29 MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells De Rosa, Piergiuseppe Severi, Federica Zadran, Suleman Khan Russo, Marco Aloisi, Sara Rigamonti, Alberto Capranico, Giovanni Milazzo, Giorgio Perini, Giovanni Int J Mol Sci Article Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB’s mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations, MYCN amplification is the most correlated event with poor outcomes. MYCN is involved in the regulation of several cellular mechanisms, including cell cycle. Thus, studying the influence of MYCN overexpression in the G1/S transition checkpoint of the cell cycle may unveil novel druggable targets for the development of personalized therapeutical approaches. Here, we show that high expression of E2F3 and MYCN correlate with poor prognosis in NB despite the RB1 mRNA levels. Moreover, we demonstrate through luciferase reporter assays that MYCN bypasses RB function by incrementing E2F3-responsive promoter activity. We showed that MYCN overexpression leads to RB inactivation by inducing RB hyperphosphorylation during the G1 phase through cell cycle synchronization experiments. Moreover, we generated two MYCN-amplified NB cell lines conditionally knockdown (cKD) for the RB1 gene through a CRISPRi approach. Indeed, RB KD did not affect cell proliferation, whereas cell proliferation was strongly influenced when a non-phosphorylatable RB mutant was expressed. This finding revealed the dispensable role of RB in regulating MYCN-amplified NB’s cell cycle. The described genetic interaction between MYCN and RB1 provides the rationale for using cyclin/CDK complexes inhibitors in NBs carrying MYCN amplification and relatively high levels of RB1 expression. MDPI 2023-03-12 /pmc/articles/PMC10049239/ /pubmed/36982482 http://dx.doi.org/10.3390/ijms24065408 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Rosa, Piergiuseppe Severi, Federica Zadran, Suleman Khan Russo, Marco Aloisi, Sara Rigamonti, Alberto Capranico, Giovanni Milazzo, Giorgio Perini, Giovanni MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title | MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title_full | MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title_fullStr | MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title_full_unstemmed | MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title_short | MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells |
title_sort | mycn amplification, along with wild-type rb1 expression, enhances cdk4/6 inhibitors’ efficacy in neuroblastoma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049239/ https://www.ncbi.nlm.nih.gov/pubmed/36982482 http://dx.doi.org/10.3390/ijms24065408 |
work_keys_str_mv | AT derosapiergiuseppe mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT severifederica mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT zadransulemankhan mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT russomarco mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT aloisisara mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT rigamontialberto mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT capranicogiovanni mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT milazzogiorgio mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells AT perinigiovanni mycnamplificationalongwithwildtyperb1expressionenhancescdk46inhibitorsefficacyinneuroblastomacells |